Skip to main content

Table 2 Echocardiographic parameters

From: Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction

 

sham + vehicle

sham + dapa

sham + T-1095

MI + vehicle

MI + dapa

MI + T-1095

N

12

7

6

20

12

14

MI size (%)

44 ± 2

38 ± 2

40 ± 2

FS (%)

53 ± 1

55 ± 3

50 ± 3

19 ± 1*

19 ± 1*

16 ± 1*

EF (%)

83 ± 1

84 ± 2

80 ± 3

37 ± 1*

37 ± 1*

31 ± 2*†‡

LV mass corr. (mg)

684 ± 26

608 ± 35*

578 ± 41

827 ± 36*

800 ± 41*

759 ± 39

LVIDd (mm)

6.73 ± 0.08

6.62 ± 0.18*

6.50 ± 0.07*

9.17 ± 0.15*

9.21 ± 0.18*

9.05 ± 0.11*

LVIDs (mm)

3.17 ± 0.09

3.01 ± 0.25

3.25 ± 0.18

7.47 ± 0.17*

7.48 ± 0.20*

7.64 ± 0.11*

Volume s (μl)

63 ± 4

52 ± 6

56 ± 10

359 ± 28*

371 ± 32*

402 ± 18*

Volume d (μl)

289 ± 15

272 ± 19

223 ± 13

574 ± 25*

555 ± 31*

556 ± 19*

  1. EF ejection fraction, FS fractional shortening, LV mass corr left ventricle mass corrected, LVPW left ventricular posterior wall, LVIDd left ventricle internal diameter in diastole, LVIDs left ventricle internal dimension in systole
  2. * p < 0.05 vs. sham + vehicle group;  p < 0.05 vs. MI + vehicle group;  p < 0.05 vs. MI + dapagliflozin group